IP Verse

Stimulators And/Or Activators Of Soluble Guanylate Cyclase (Sgc) In Combination With An Inhibitor Of Neutral Endopeptidase (Nep Inhibitor) And/Or An Angiotensin Aii Antagonist And The Use Thereof - EP3325013

The patent EP3325013 was granted to Bayer on Jul 19, 2023. The application was originally filed on Jul 15, 2016 under application number EP16739146A. The patent is currently recorded with a legal status of "Patent Maintained As Amended".

EP3325013

BAYER
Application Number
EP16739146A
Filing Date
Jul 15, 2016
Status
Patent Maintained As Amended
Jun 16, 2023
Grant Date
Jul 19, 2023
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

PAJAROJun 16, 2021ALT -

Patent Citations (104) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication Number
DESCRIPTIONEP0443983
DESCRIPTIONEP0555175
DESCRIPTIONEP1948158
DESCRIPTIONUS5399578
DESCRIPTIONWO0002851
DESCRIPTIONWO0006568
DESCRIPTIONWO0006569
DESCRIPTIONWO0119776
DESCRIPTIONWO0119778
DESCRIPTIONWO0119780
DESCRIPTIONWO02070459
DESCRIPTIONWO02070460
DESCRIPTIONWO02070461
DESCRIPTIONWO02070462
DESCRIPTIONWO02070510
DESCRIPTIONWO02092596
DESCRIPTIONWO0236120
DESCRIPTIONWO0242299
DESCRIPTIONWO0242300
DESCRIPTIONWO0242301
DESCRIPTIONWO0242302
DESCRIPTIONWO03004503
DESCRIPTIONWO03009545
DESCRIPTIONWO03095451
DESCRIPTIONWO03097063
DESCRIPTIONWO2004009589
DESCRIPTIONWO2007045366
DESCRIPTIONWO2007045367
DESCRIPTIONWO2007045369
DESCRIPTIONWO2007045370
DESCRIPTIONWO2007045433
DESCRIPTIONWO2007124854
DESCRIPTIONWO2007128454
DESCRIPTIONWO2008031513
DESCRIPTIONWO2008061657
DESCRIPTIONWO2008119457
DESCRIPTIONWO2008119458
DESCRIPTIONWO2009032249
DESCRIPTIONWO2009068652
DESCRIPTIONWO2009071504
DESCRIPTIONWO2009123316
DESCRIPTIONWO2009127338
DESCRIPTIONWO2010065275
DESCRIPTIONWO2010079120
DESCRIPTIONWO2010102717
DESCRIPTIONWO2011051165
DESCRIPTIONWO2011115804
DESCRIPTIONWO2011119518
DESCRIPTIONWO2011141409
DESCRIPTIONWO2011147809
DESCRIPTIONWO2011149921
DESCRIPTIONWO2012003405
DESCRIPTIONWO2012004258
DESCRIPTIONWO2012004259
DESCRIPTIONWO2012028647
DESCRIPTIONWO2012059548
DESCRIPTIONWO2012059549
DESCRIPTIONWO2012064559
DESCRIPTIONWO2012076466
DESCRIPTIONWO2012139888
DESCRIPTIONWO2012143510
DESCRIPTIONWO2012152629
DESCRIPTIONWO2012152630
DESCRIPTIONWO2012165399
DESCRIPTIONWO2013004785
DESCRIPTIONWO2013030288
DESCRIPTIONWO2013104597
DESCRIPTIONWO2013104598
DESCRIPTIONWO2013104703
DESCRIPTIONWO2013131923
DESCRIPTIONWO2013174736
DESCRIPTIONWO2014012934
DESCRIPTIONWO2014012935
DESCRIPTIONWO2014047111
DESCRIPTIONWO2014047325
DESCRIPTIONWO2014068095
DESCRIPTIONWO2014068099
DESCRIPTIONWO2014068104
DESCRIPTIONWO2014084312
DESCRIPTIONWO2014128109
DESCRIPTIONWO2014131741
DESCRIPTIONWO2014131760
DESCRIPTIONWO2014144100
DESCRIPTIONWO2014195333
DESCRIPTIONWO2015004105
DESCRIPTIONWO2015008885
DESCRIPTIONWO2015008886
DESCRIPTIONWO2015018808
DESCRIPTIONWO2015018814
DESCRIPTIONWO9816223
DESCRIPTIONWO9816507
DESCRIPTIONWO9823619
INTERNATIONAL-SEARCH-REPORTWO2011056511
INTERNATIONAL-SEARCH-REPORTWO2011147809
INTERNATIONAL-SEARCH-REPORTWO2012139888
INTERNATIONAL-SEARCH-REPORTWO2016087342
OPPOSITIONEP1948158
OPPOSITIONWO03095451
OPPOSITIONWO2011056511
OPPOSITIONWO2011147809
OPPOSITIONWO2012139888
OPPOSITIONWO2014131760
OPPOSITIONWO2014144100
OPPOSITIONWO2017013010

Non-Patent Literature (NPL) Citations (31) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference Text
DESCRIPTION- GOLDBLATT ET AL., PROC NATL ACAD SCI, (1976), vol. 73, pages 1722 - 1724
DESCRIPTION- GU J. ET AL., J CLIN PHARMACOL., (201004), vol. 50, no. 4, pages 401 - 14
DESCRIPTION- K. WITTE; K. HU; J. SWIATEK; C. MÜSSIG; G. ERTL; B. LEMMER, "Experimental heart failure in rats: effects on cardiovascular circadian rhythms and on myocardial ß-adrenergic signaling", CARDIOVASC. RES., (2000), vol. 47, no. 2, pages 203 - 405
DESCRIPTION- PAGE ET AL., SCIENCE, (1939), vol. 89, pages 2307 - 2308
DESCRIPTION- REDFIELD ET AL., CIRCULATION, (1993), vol. 87, pages 2016 - 2022
EXAMINATION- Johannes-Peter Stasch ET AL, "Renal effects of soluble guanylate cyclase stimulators and activators: A review of the preclinical evidence", CURRENT OPINION IN PHARMACOLOGY, NL, (20150401), vol. 21, doi:10.1016/j.coph.2014.12.014, ISSN 1471-4892, pages 95 - 104, XP055545669
EXAMINATION- BEYER C ET AL, "Stimulation of the soluble guanylate cyclase (sGC) inhibits fibrosis by blocking non-canonical TGF[beta] signalling", ANNALS OF THE RHEUMATIC DISEASES, BRITISH MEDICAL ASSOCIATION, GB, vol. 74, no. 7, doi:10.1136/ANNRHEUMDIS-2013-204508, ISSN 0003-4967, (20150701), pages 1408 - 1416, (20140223), XP009509498
EXAMINATION- J.-P. Stasch ET AL, "Soluble Guanylate Cyclase as an Emerging Therapeutic Target in Cardiopulmonary Disease", Circulation, US, (20110523), vol. 123, no. 20, doi:10.1161/CIRCULATIONAHA.110.981738, ISSN 0009-7322, pages 2263 - 2273, XP055440845
INTERNATIONAL-SEARCH-REPORT- JOHN J.V. MCMURRAY ET AL, "Angiotensin-Neprilysin Inhibition versus Enalapril in Heart Failure", NEW ENGLAND JOURNAL OF MEDICINE, (20140911), vol. 371, no. 11, doi:10.1056/NEJMoa1409077, ISSN 0028-4793, pages 993 - 1004, XP055175908 [Y] 1-11 * the whole document * * insbesondere * * abstract * * Discussion *
INTERNATIONAL-SEARCH-REPORT- M. KOMAJDA ET AL, "Heart failure with preserved ejection fraction: a clinical dilemma", EUROPEAN HEART JOURNAL, GB, (20140311), vol. 35, no. 16, doi:10.1093/eurheartj/ehu067, ISSN 0195-668X, pages 1022 - 1032, XP055305898 [I] 1-11 * the whole document * * besonders * * table 4 * * page 1030, column 2 *
OPPOSITION- Anonymous, "DER ÖSTERREICHISCHEN KARDIOLOGISCHEN GESELLSCHAFT,", skriptum Kongressjournal, (20140500), vol. 11, no. 5, pages 1 - 30, XP055818587
OPPOSITION- Anonymous, "International Nonproprietary Names for Pharmaceutical Substances [INN]", WHO Drug Information, (20130000), vol. 27, no. 2, pages 1 - 75, XP055818671
OPPOSITION- Anonymous, "Leitlinien für das Management der arteriellen Hypertonie", ESC Pocket Guidelines, (20130000), pages 1 - 51, XP055818620
OPPOSITION- ARMSTRONG PW et al., "Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction", N Engl J Med, (20200000), vol. 382, no. 20, pages 1883 - 1893, XP055818613
OPPOSITION- BONDERMAN et al., "Acute Hemodynamic Effects of Riociguat in Patients With Pulmonary Hypertension Associated With Diastolic Heart Failure (DILATE-1)", CHEST, (20140000), vol. 146, no. 5, pages 1274 - 1285, XP055818628
OPPOSITION- Burkert Pieske 1, Javed Butler, Gerasimos Filippatos, Carolyn Lam, Aldo Pietro Maggioni, Piotr Ponikowski, Sanjiv Shah, Scott Solomon, Elisabeth Kraigher-Krainer, Eliana Tibana Samano, Andrea Viviana Scalise, Katharina Müller, Lothar Roessig, Mihai Gheorghiade, "Rationale and design of the SOluble guanylate Cyclase stimulatoR in heArT failurE Studies (SOCRATES)", European Journal of Heart Failure, (20140000), vol. 16, pages 1026 - 1038, XP055818580
OPPOSITION- Frey Reiner, Wolfgang Mück, Sigrun Unger, Ulrike Artmeier-Brandt, Gerrit Weimann, Georg Wensing, "Single-dose pharmacokinetics, pharmacodynamics, tolerability, and safety of the soluble guanylate cyclase stimulator BAY 63-2521: an ascending-dose study in healthy male volunteers", J Clin Pharmacol, (20080000), vol. 48, pages 926 - 934, XP055818570
OPPOSITION- FRIEBE et al., "From bedside to bench - meeting report of the 7th International Conference on 'cGMP: generators, effectors and therapeutic implication' in Trier, Germany, from June 19th to 21st 2015", Naunyn-Schmiedeberg's Arch Pharmacol, (20150000), vol. 388, pages 1237 - 1246, XP055818562
OPPOSITION- Goel Sunny , Avraham Miller, Abhishek Sharma, Umesh Gidwani And Jacob Shani, "Treatment Modalities for Heart Failure with Preserved Ejection Fraction (HFpEF) - Current State of Evidence and Future Perspective", J Clin Exp Cardiolog, (20150000), vol. 6, no. 7, pages 1 - 9, XP055818519
OPPOSITION- Pardeep S Jhund , Brian Claggett, Milton Packer, Michael R Zile, Adriaan A Voors, Burkert Pieske, Martin Lefkowitz, Victor Shi, Toni Bransford, John J V McMurray, Scott D Solomon, "Independence of the blood pressure lowering effect and efficacy of the angiotensin receptor neprilysin inhibitor, LCZ696, in patients with heart failure with preserved ejection fraction: an analysis of the PARAMOUNT trial", European Journal of Heart Failure, (20140000), vol. 16, pages 671 - 677, XP055818651
OPPOSITION- RITZMANN P., "Kombinierte Antihypertensiva", pharma-kritik, (20090000), vol. 18, pages 69 - 72, XP055818579
OPPOSITION- TSCHÖPE et al., "Neue Therapiekonzepte zur Herzinsuffizienz mit erhaltener Ejektionsfraktion", Herz, (20150000), vol. 40, pages 194 - 205, XP055818597
OPPOSITION- VON LUEDER et al., "New medical therapies for heart failure", Nat. Rev. Cardiol, (20150929), pages 1 - 11, XP055818508
OPPOSITION- Witte K., K Hu, J Swiatek, C Müssig, G Ertl, B Lemmer, "Experimental heart failure in rats: effects on cardiovascular circadian rhythms and on myocardial beta-adrenergic signaling", Cardiovasc Res, (20000000), vol. 47, pages 350 - 358, XP055818743
OPPOSITION- Johannes-Peter Stasch; Jens Schlossmann; Berthold Hocher, "Renal effects of soluble guanylate cyclase stimulators and activators: A review of the preclinical evidence", Current Opinion in Pharmacology, (20150000), vol. 21, pages 95 - 104, XP055545669
OPPOSITION- WAEBER B. et al., "Blood-pressure reduction with LCZ696", Lancet, (20100000), vol. 375, doi:10.1016/S0140-6736(10)60363-7, pages 1228 - 1229, XP027490757
OPPOSITION- MCMURRAY et al., "Angiotensin-Neprilysin Inhibition versus Enalapril in Heart Failure", N Engl J Med, (20140000), vol. 371, no. 11, doi:10.1056/NEJMoa1409077, pages 993 - 1004, XP055175908
OPPOSITION- Beyer C; Palumbo-Zerr K; Mancuso R; Distler A; Dees C; Zerr P; Huang J; Maier C; Schett G; Distler J H W; Zenzmaier C; Berger P; Zenzmaier C; Pachowsky M L; Friebe A; Sandner P; Sandner P; Distler O, "Stimulation of the soluble guanylate cyclase (sGC) inhibits fibrosis by blocking non-canonical TGFβ signalling", Ann Rheum Dis, (20150000), vol. 74, no. 7, pages 1408 - 1416, XP009509498
OPPOSITION- Johannes-Peter Stasch, Pál Pacher, and Oleg V. Evgenov, "Soluble Guanylate Cyclase as an Emerging Therapeutic Target in Cardiopulmonary Disease", Circulation, (20110000), vol. 123, no. 20, pages 2263 - 2273, XP055440845
OPPOSITION- Gu J; Noe A; Chandra P; Al-Fayoumi S; Ligueros-Saylan M; Sarangapani R; Maahs S; Ksander G; Rigel D F; Jeng A Y; Lin T H; Zheng W; Dole W P, "Pharmacokinetics and pharmacodynamics of LCZ696, a novel dual-acting angiotensin receptor-neprilysin inhibitor (ARNi)", Journal of Clinical Pharmacology, (20100000), vol. 50, no. 4, pages 401 - 414, XP002718352
OPPOSITION- ORSO et al., "Newest additions to heart failure treatment", Expert Opin. Pharmacother, (20140900), vol. 15, no. 13, pages 1849 - 1861, XP055306645

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents